Yesterday, I linked an article written by Michael Fumento, which noted that a potential cure for juvenile diabetes using adult stem cells is not being funded by the Juvenile Diabetes Research Foundation, even though the technique cured mice with late stage disease.
Fumento wanted to follow up with a “Part 2” commentary. But, it appears that somebody doesn’t want this truth widely disseminated. According to Fumento, his syndicate, Scripps Howard refused to publish the article, based on it allegedly being a “diatribe.” What? Fumento’s tone is utterly reasonable. The facts about which he opines are indisputable. Indeed, SCIENCE DID publish the study demonstrating that adult spleen stem cells completely cured mice with late stage juv. diabetes. Despite this amazing success, the JDRF DID refuse to fund human trials. Finally, the JDRF DID fund Proposition 71, which created a right to therapeutic cloning, to the tune of about $2 million. Yet, even IF that technology EVER becomes an effective treatment for juv. diabetes, it is at least a decade or more away.
This raises an important question: Is the JDRF most interested in finding a cure for juvenile diabetes or in promoting embryonic stem cell research and therapeutic human cloning? Surely, this is a topic worthy of being explored by a knowledgeable pundit. And if so, why the censorship?
You have a decision to make: double or nothing.
For this week only, a generous supporter has offered to fully match all new and increased donations to First Things up to $60,000.
In other words, your gift of $50 unlocks $100 for First Things, your gift of $100 unlocks $200, and so on, up to a total of $120,000. But if you don’t give, nothing.
So what will it be, dear reader: double, or nothing?
Make your year-end gift go twice as far for First Things by giving now.
